Biodesix vs Harvard Bioscience
Biodesix and Harvard Bioscience are similar in size: $88.5m and $86.5m of revenue in their latest fiscal years. Biodesix grew faster (24.1% against -8.1%). Biodesix kept more of each dollar of sales as profit: a net margin of -39.8% against -65.5%.
| Latest fiscal year | BiodesixBDSX, 2025 | Harvard BioscienceHBIO, 2025 |
|---|---|---|
| Revenue | $88.5m | $86.5m |
| Revenue growth | 24.1% | -8.1% |
| Net income | −$35.3m | −$56.7m |
| Operating margin | -31.5% | -56.1% |
| Net margin | -39.8% | -65.5% |
| Return on equity | — | -147.1% |
| Free cash flow | −$23.5m | $5.5m |
| Cash | $19.0m | $8.6m |
| Total debt | $50.0m | $40.0m |
| Debt to equity | — | 291.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 334 | 339 |
| Market value | $223m | $40.1m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 56 (Moderate) |
| Insider trades, 12 months | 6 buys, 20 sales | 5 buys, 0 sales |